SCHEMBL14744790

SCHEMBL14744790

Cn1c(CO[Si](C)(C)C(C)(C)C)cc2cc(C(=O)Cc3ccc(F)cc3)ccc21

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 1/20 0.39
LMNA P02545 3/20 0.36
TP53 P04637 3/20 0.36
POLB P06746 1/20 0.36
MAPT P10636 3/20 0.34
KDM4E B2RXH2 2/20 0.34
HSD17B10 Q99714 2/20 0.34
ALDH1A1 P00352 2/20 0.34
HPGD P15428 1/20 0.34
SMN1; SMN2 Q16637 4/20 0.33
HTT P42858 2/20 0.33
ACSS2 Q9NR19 1/20 0.33
PTGES O14684 1/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2C9 P11712 1/20 0.33
CYP2C19 P33261 1/20 0.33
NPC1 O15118 2/20 0.33
RAB9A P51151 2/20 0.33
ALOX15 P16050 1/20 0.32
MAPK1 P28482 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14745543 0.84 SIGMAR1 (0.34) MAPTHPGDSMN1; SMN2NPC1RAB9A
SCHEMBL14745203 0.82 HSD17B3 (0.37) MAPTKDM4EHSD17B10ALDH1A1HPGD
SCHEMBL14745668 0.82 HCAR3 (0.40) KDM4EHSD17B10ALDH1A1HPGDSMN1; SMN2
SCHEMBL16441005 0.81 LMNA (0.44) IDO1LMNATP53POLBMAPT
SCHEMBL14745032 0.77 NPC1 (0.35) LMNAPOLBMAPTHSD17B10SMN1; SMN2
SCHEMBL14745030 0.77 NPC1 (0.35) LMNAPOLBMAPTHSD17B10SMN1; SMN2
SCHEMBL14744689 0.76 MLYCD (0.34) KDM4EHSD17B10ALDH1A1HPGDSMN1; SMN2
SCHEMBL14745193 0.73 MCL1 (0.41) TP53MAPTALDH1A1SMN1; SMN2NPC1
SCHEMBL14745877 0.72 HPGD (0.35) MAPTKDM4EHSD17B10ALDH1A1HPGD
SCHEMBL14744975 0.71

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9409905-B2 Antibacterial compounds and methods for use PTC THERAPEUTICS, INC. (US) 2016-08-09 US disclosed
US-20150038437-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC THERAPEUTICS, INC. (US) 2015-02-05 US disclosed
EP-2750504-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC Therapeutics, Inc. (US) 2014-07-09 EP disclosed
WO-2013033258-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC THERAPEUTICS, INC. (US) 2013-03-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150038437-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE MRPL21, SLC11A2, CLPP IDO1 4322/4885LMNA 2119/4885TP53 2640/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.